Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB161734 in Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT06179160Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 1, open-label trial of INCB161734 in solid tumor (6 arms), sponsored by Incyte. Primary endpoints: Dose Limiting Toxicities at 28 days, Treatment-emergent Adverse Events and 1 more. Started Jan 2024; status: recruiting.
02
Drugs
INCB161734
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06179160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06179160.